An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.
Latest Information Update: 18 Sep 2024
Price :
$35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms PAZEC
- 11 Oct 2016 Status changed from recruiting to completed,according to the results published at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Primary endpoint (Progression free survival at 3 months) has been met,according to the results published at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress